

State-of-the-art-facility

Manufacturing Facility at Indrad



TORNENT PHARMACEUTICALS LIMITED

Structure


Torrent Group:

- Pharmaceuticals
 - Manufacturing
 - Discovery & Development
 - Sales & Marketing
- Power
 - Generation
 - Transmission & Distribution
 - Cables



Torrent Group - At a Glance

TORRENT GROUP is a US \$ 994 Million conglomerate with a dominant position in HEALTHCARE and ENERGY



Evolution

- 1959 Pharma Operations
- 1989 Formulation Facility at Indrad
- 1990 Manufacturing tie-up with Novo Nordisk A/S, Denmark, for Insulin
- 1992 API Facility at Indrad
- 1996 State-of-the-art Research Centre
- 2001 Modernization & up gradation of formulation unit
- 2003 Modernization & up-gradation of API Facilities
- 2005 Formulation Manufacturing facility at Baddi



Global Reach

- Operations in 50 Countries.
- Wholly owned subsidiaries in Russia, Germany, Brazil, USA, Japan, Mexico, Australia & Philippines.

Major Regions:

- Europe, Brazil, Russia, CIS, Africa, S.E. Asia, Sri Lanka, Middle East, Poland, Romania, Hungary etc...

Portfolio:

- Ethical Formulations
- Branded Generics in semi regulated markets
- Active Pharmaceutical Ingredients



Manufacturing Facility at Indrad, Gujarat

- Land - 194,000 sq. meters
- Built-up Area Formulation- 53,000 sq. meters
- Built-up Area API- 14,000 sq. meters
- Formulations
 - Solid Oral Dosage Forms (Tablets & Hard Gelatin Capsules)
 - Injectables (Vials & Ampoules)
- API
 - Multi Product Facility



Quality Policy

“ We the employees of Torrent Pharmaceuticals Limited are committed to achieve excellence in quality standards and always supply products as per global requirements.

We shall create an environment where each employee contributes to all aspects of our business processes. We shall strive for continuous improvement to meet with customer satisfaction.”

DR. C. DUTT

DIRECTOR





AWARDS & CERTIFICATIONS

Regulatory Approvals

| Year | Regulatory Authority | Approvals For |
|-------------|--|----------------------------|
| November'06 | USFDA | Formulation(Tablet) & API |
| November'06 | MoH UKRAINE | Tablets & Capsules |
| July'06 | BFDA, Taiwan | Tablets & Capsules |
| December-05 | BfARm, Germany | Tablets & Capsules |
| February-05 | Food & Drug Authority, Tanzania | Formulations |
| February-05 | Ministry of Health, Indonesia | Formulations |
| February-05 | TGA, Australia | Formulations - Tablets |
| October-04 | MHRA, UK | Formulations - Tablets |
| March-04 | MCAZ - Zimbabwe | Formulations |
| November-03 | INVIMA, Columbia | Formulations |
| October-03 | European Union Germany | API & Formulations Tablets |
| March-03 | MCC - South Africa | Formulations |
| January-03 | MOH - Latvia | API & Formulations |
| January-03 | National Institute of Pharmacy - Hungery | API & Formulations Tablets |
| January-02 | ANVISA - Brazil | Formulations |

Other Accreditations

| | | |
|--|---|------|
|  BRITISH SAFETY CERTIFICATE (4 STAR RATING) - 2003 | - | 2003 |
|  NABL - ISO 17025 - 2005 | - | 2006 |



Safety, Health & Environment

- Zero Discharge Policy - Plant effluent is fully treated to stringent in-house norms
- Safety systems based on on-site & off-site emergency plans
- cGMP norms of hygiene and safety followed.
- Process & other equipment provided with vacuum /scrubber / Filtered Air systems
- Multiple Effect Evaporator
- Solar Pond for evaporation.



Safety, Health & Environment

- Care for Environment
 - Rain harvesting to conserve ground water level
 - Water recycle & Conservation
 - Use of renewable energy (Solar Pond)- Carbon Dioxide reduction scheme.
- Fire Protection Systems in place
- Safety aids provided to all operating personnel.
- Adequate facility for medical treatment.
- Periodic medical examination for all employees.
- Personnel trained to deal with emergencies

